Syneos Health (Nasdaq:SYNH) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

SYNH Overzicht aandelen

Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company.

SYNH fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	3/6
Prestaties in het verleden	1/6
Financiële gezondheid	3/6
Dividenden	0/6

Beloningen

Verhandeld tegen 25.3% onder onze schatting van de reële waarde

De winst zal naar verwachting met 33.7% per jaar groeien

Risicoanalyse

De schulden worden niet goed gedekt door de operationele kasstroom

Grote eenmalige posten die de financiële resultaten beïnvloeden

Winstmarges (1.3%) zijn lager dan vorig jaar (5.1%)

Syneos Health, Inc. Concurrenten

Sotera Health

NasdaqGS:SHC

US$4.6b

Stevanato Group

NYSE:STVN

US$5.5b

Charles River Laboratories International

NYSE:CRL

US$10.0b

Bruker

NasdaqGS:BRKR

US$10.2b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Syneos Health
Historische aandelenkoersen
Huidige aandelenkoers	US$42.98
52 Week Hoogtepunt	US$52.23
52 Week Laag	US$22.89
Bèta	1.58
11 maand verandering	0.66%
3 maanden verandering	1.99%
1 Jaar Verandering	-8.84%
33 jaar verandering	-23.06%
5 jaar verandering	-10.61%
Verandering sinds IPO	109.76%

Recent nieuws en updates

Recent updates

Is There An Opportunity With Syneos Health, Inc.'s (NASDAQ:SYNH) 49% Undervaluation?

Jun 18

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Jun 03

We Think Syneos Health (NASDAQ:SYNH) Can Stay On Top Of Its Debt

May 19

Do Syneos Health's (NASDAQ:SYNH) Earnings Warrant Your Attention?

Apr 08

Syneos Health: Upside Opportunity After Unexpected Correction In CRO Market, M&A Rumors

Mar 27

Is Now An Opportune Moment To Examine Syneos Health, Inc. (NASDAQ:SYNH)?

Mar 05

Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Feb 18

Are Investors Undervaluing Syneos Health, Inc. (NASDAQ:SYNH) By 39%?

Feb 03

With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Is Interesting

Jan 04

Syneos Health's Double-Digit Revenue Growth Sets The Tone For A Strong 2022

Dec 03

Is It Too Late To Consider Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Dec 03

Rendement voor aandeelhouders

	SYNH	US Life Sciences	US Markt
7D	0.6%	-0.3%	-0.4%
1Y	-8.8%	17.6%	34.1%

Rendement versus industrie: SYNH overtrof de US Life Sciences industrie, die het afgelopen jaar een rendement 17.6 % opleverde.

Rendement versus markt: SYNH presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 34.1 % opleverde.

Prijsvolatiliteit

Is SYNH's price volatile compared to industry and market?
SYNH volatility
SYNH Average Weekly Movement	0.3%
Life Sciences Industry Average Movement	8.8%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: SYNH heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van SYNH is het afgelopen jaar gedaald van 9% naar 0%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2010	28,768	Michelle Keefe	www.syneoshealth.com

Syneos Health, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Syneos Health zich tot de beurswaarde?
SYNH fundamentele statistieken
Marktkapitalisatie	US$4.46b
Inkomsten(TTM)	US$71.22m
Inkomsten(TTM)	US$5.42b

62.6x

Koers/Winstverhouding

0.8x

P/S-verhouding

Is SYNH overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SYNH resultatenrekening (TTM)
Inkomsten	US$5.42b
Kosten van inkomsten	US$4.22b
Brutowinst	US$1.20b
Overige uitgaven	US$1.13b
Inkomsten	US$71.22m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.69
Brutomarge	22.14%
Nettowinstmarge	1.31%
Schuld/Eigen Vermogen Verhouding	75.8%

Hoe presteerde SYNH op de lange termijn?

Bekijk historische prestaties en vergelijking

SYNH Overzicht aandelen

Beloningen

Risicoanalyse

Syneos Health, Inc. Concurrenten

NasdaqGS:SHC

US$4.6b

NYSE:STVN

US$5.5b

NYSE:CRL

US$10.0b

NasdaqGS:BRKR

US$10.2b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Syneos Health Files Form 15

Syneos Health, Inc. Announces Chief Executive Officer Changes

Syneos Health, Inc. Announces Management Changes

Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C completed the acquisition of Syneos Health, Inc. (NasdaqGS:SYNH) from a group of shareholders.

Syneos Health Names Terttu Haring President, Clinical Sites & Patients

Levi & Korsinsky Notifies Syneos Health, Inc. Investors of A Class Action Lawsuit and Upcoming Deadline

Recent updates

Syneos Health Files Form 15

Syneos Health, Inc. Announces Chief Executive Officer Changes

Syneos Health, Inc. Announces Management Changes

Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C completed the acquisition of Syneos Health, Inc. (NasdaqGS:SYNH) from a group of shareholders.

Syneos Health Names Terttu Haring President, Clinical Sites & Patients

Levi & Korsinsky Notifies Syneos Health, Inc. Investors of A Class Action Lawsuit and Upcoming Deadline

Consensus EPS estimates fall by 70%

The Klein Law Firm Announces That a Class Action Complaint Has Been Filed on Behalf of Shareholders of Syneos Health, Inc

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Syneos Health, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Syneos Health, Inc

Syneos Health Appoints Hillary Bochniak as Chief Human Resources Officer

Syneos Health, Inc. Appoints Batisha Anson to Global Head, Patient Diversity and Health Equity

Consensus EPS estimates fall from profit to US$0.31 loss, revenue upgraded

Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C entered into an agreement to acquire Syneos Health, Inc. (NasdaqGS:SYNH) in a transaction valued at approximately $7.5 billion.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 17%

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Does Syneos Health (NASDAQ:SYNH) Have A Healthy Balance Sheet?

Is Syneos Health, Inc. (NASDAQ:SYNH) Trading At A 40% Discount?

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Syneos Health, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Consensus EPS estimates fall by 11%

Price target decreased by 10% to US$36.95

Syneos Health, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Syneos Health, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Should You Investigate Syneos Health, Inc. (NASDAQ:SYNH) At US$34.33?

Is Syneos Health (NASDAQ:SYNH) Using Too Much Debt?

High number of new directors

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Syneos Health, Inc. Revises Earnings Guidance for the Fiscal Year 2022

Here's Why Syneos Health (NASDAQ:SYNH) Has Caught The Eye Of Investors

Syneos Health Adds Hub Patient Suite to Deployment Solutions Business

Syneos Health, Inc. to Report Q3, 2022 Results on Nov 04, 2022

Syneos Health, Inc. Announces Executive Changes

Price target decreased to US$69.73

Syneos, Datavant expand partnership on data analytics for clinical trials

Investor sentiment deteriorated over the past week

Syneos Health falls 13% after update on outlook

When Should You Buy Syneos Health, Inc. (NASDAQ:SYNH)?

Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Syneos Health, Inc. (NasdaqGS:SYNH) acquired Boco Digital Media, LLC.

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Syneos Health, Inc. Provides Earnings Guidance for the Third Quarter of 2022

Syneos Health Q2 2022 Earnings Preview

With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Makes An Interesting Case

Syneos Health, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Syneos: Upside Could Be Priced In, Valuations Unsupportive

Is There An Opportunity With Syneos Health, Inc.'s (NASDAQ:SYNH) 49% Undervaluation?

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

We Think Syneos Health (NASDAQ:SYNH) Can Stay On Top Of Its Debt

Consensus forecasts updated

High number of new directors

Syneos Health, Inc. Revises Earnings Guidance for the Fiscal Year 2022

First quarter 2022 earnings: EPS misses analyst expectations

Syneos Health Announces Executive Promotions

Syneos Health, Inc., Annual General Meeting, May 25, 2022

Syneos Health, Inc. to Report Q1, 2022 Results on Apr 29, 2022